Navigation Links
JCI online early table of contents: Jan. 2, 2008
Date:1/2/2008

EDITOR'S PICK

Il-22 gene delivers the goods and decreases intestinal inflammation

There are two major types of inflammatory bowel disease (IBD), Crohn disease (CD) and ulcerative colitis (UC). Conflicting reports have indicated that the soluble factor IL-22 can have both IBD promoting and IBD controlling effects. But now, Atsushi Mizoguchi and colleagues at Massachusetts General Hospital, Boston, have established that IL-22 ameliorates disease in a mouse model of UC.

Expression of IL-22 is much higher in the intestines of individuals with CD than UC. To investigate the role of IL-22 in IBD, the authors used a new microinjection-based strategy to deliver the gene that makes IL-22 to the walls of the intestine of mice who suffer from an intestinal disease that models UC. Delivery of the Il-22 gene ameliorated local intestinal inflammation through enhanced mucus production. Consistent with this, when the same strategy was used to deliver a gene that makes a protein that neutralizes IL-22, IL-22binding protein, to the walls of the intestines of normal mice it enhanced chemical-induced intestinal inflammation. The authors therefore suggest that individuals with UC might benefit from local delivery of the IL-22 gene to their intestines.

TITLE: IL-22 ameliorates intestinal inflammation in a mouse model of ulcerative colitis

AUTHOR CONTACT:
Atsushi Mizoguchi
Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Phone: (617) 726-2588; Fax: (617) 726-2365; E-mail: amizoguchi@partners.org.

View the PDF of this article at: https://www.the-jci.org/article.php?id=33194


EDITOR'S PICK

Epilepsy and brain pathology linked together by the protein ADK

The brain of individuals who suffer from epilepsy is characte
'/>"/>

Contact: Karen Honey
press_releases@the-jci.org
215-573-1850
Journal of Clinical Investigation
Source:Eurekalert

Page: 1 2 3 4 5 6 7 8 9

Related medicine news :

1. HIV denialists spread misinformation online -- consequences could be deadly; and more
2. Consequences of online HIV denial; and more
3. Online Epidemic Gives Clues to Bird Flu Spread
4. MedHelp to Add Top Stanford Surgeons and Specialized Forums to Online Health Community
5. Online Celebrity Shoe Charity Auction for Womens Heart Health Opens Bidding
6. Syndicom to Launch Online Community for DePuy Spine
7. Elder Caregiving Site ShirleyBOARD.com Wins WebAward for Outstanding Online Community
8. Peer-Reviewed, Online Database Showcases Local, County and State Pandemic Planning
9. CIGNA Behavioral Health Offers Members Online Provider Profiles
10. Dynamic Energy Systems Goes Online and On-Demand
11. North Shore-LIJ Health System Begins Online Posting of Hospital Infection Rates, Other Performance Information
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Lentigen Awarded Phase I SBIR Grant for Hepatitis C Vaccine 2Perrigo Confirms Filing for Generic Version of Clobex(R) Spray and Announcement of Lawsuit by Galderma and Dermalogix 2Perrigo Confirms Filing for Generic Version of Clobex(R) Spray and Announcement of Lawsuit by Galderma and Dermalogix 3Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium 2Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium 3Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium 4Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium 5Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium 6COMFORCE Corporation to Hold Conference Call to Discuss Second Quarter 2009 Results 53484 1COMFORCE Corporation to Hold Conference Call to Discuss Second Quarter 2009 Results 53484 2Therapy Technique Cuts Divorce Separation Rate By Nearly 50 Percent 53482 1Therapy Technique Cuts Divorce Separation Rate By Nearly 50 Percent 53482 2Micromet Receives European Orphan Drug Designation for Treatment of Acute Lymphoblastic Leukemia with BiTE Antibody Blinatumomab 13330 1Micromet Receives European Orphan Drug Designation for Treatment of Acute Lymphoblastic Leukemia with BiTE Antibody Blinatumomab 13330 2Micromet Receives European Orphan Drug Designation for Treatment of Acute Lymphoblastic Leukemia with BiTE Antibody Blinatumomab 13330 3Micromet Receives European Orphan Drug Designation for Treatment of Acute Lymphoblastic Leukemia with BiTE Antibody Blinatumomab 13330 4